Marshall Edwards licenses two anticancer compounds from Novogen

By Lisa Kerner

Erie, Pa., May 15 - Novogen Ltd. and Marshall Edwards, Inc. have formed a license agreement to develop and commercialize the oral forms of two oncology compounds, NV-196 and NV-143, according to a news release.

NV-196, currently in phase 1 human testing, is an option compound being developed for pancreatic and bile duct cancer.

NV-143 for the treatment of melanoma is in preclinical testing and has been in-licensed by Marshall Edwards.

Under the agreement, Marshall Edwards will pay a single upfront payment of $1 million to Novogen as well as milestone payments for marketing and other approvals and human testing at phases 2 and 3. Novogen will also receive 5% royalty on sales.

Marshall Edwards will fund the ongoing clinical programs and is responsible for the commercial development of the drugs.

The company is also the licensee of investigational anticancer drug phenoxodiol developed by Novogen, which is in phase 2 trials for ovarian and prostate cancer.

"The high safety profile and effectiveness that these drugs have demonstrated in preclinical studies, along with our positive clinical experience with the related compound phenoxodiol, auger well for a successful clinical program," Marshall Edwards chairman Graham Kelly said in the release.

Marshall Edwards is a clinical development oncology company majority owned by biotechnology company Novogen.

Novogen, based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.